Drug that cuts alcohol pleasure, craving OK'd

January 17, 1995|By Los Angeles Times

The first new drug in 47 years to treat alcoholism has been approved by the U.S. Food and Drug Administration, the National Institute on Alcohol Abuse and Alcoholism announced yesterday.

Unlike Antabuse, the currently used drug, which makes the user severely nauseated when he or she uses alcohol, naltrexone works by blocking both the craving for alcohol and the pleasure of getting high.

"This is the beginning of a new era . . . in alcoholism treatment," said Dr. Enoch Gordis, director of the institute, which funded testing of the drug. "This is not a 'magic bullet,' but naltrexone promises to help many patients in their struggle against a chronic relapsing disease."

Results from an ongoing clinical trial to be released today at a New York news conference show that, when combined with conventional behavioral modification, naltrexone allows as many as three-quarters of alcoholics to avoid a relapse, compared with fewer than half of those who received counseling alone.

"[We] now have a novel medical approach available that significantly increases abstinence rates and seems to reduce alcohol craving," said Dr. Joseph Volpicelli of the University of Pennsylvania.

Alcoholism is by far the most common drug abuse problem in the United States. Nearly 11 million Americans suffer from alcoholism, and as many as a third of all Americans are touched by it through a close relative or acquaintance. At least 100,000 deaths are associated with alcohol abuse each year, either from cirrhosis of the liver or from accidents caused by intoxication.

About 1 million American alcoholics seek help for their problem each year, but many drop out of treatment quickly, in part because their craving for alcohol is so great that they cannot resist the temptation. Of those who stay in the programs, more than half typically suffer a relapse within a few months.

Naltrexone was developed by the DuPont Co., now the DuPont Merck Pharmaceutical Co., for the treatment of heroin abuse and approved for that use in 1984. It targets the same receptors in the brain that produce feelings of pleasure when heroin or other opiates bind to them, but does not itself produce a "high" and is not habit-forming.

Although alcohol does not bind to those brain receptors, studies in animals and now humans show that naltrexone works equally well against it.

Patients who received the drug reported that it reduced the craving for a drink. And because it reduced pleasurable sensations from alcohol, those patients who had a drink or two during recovery were much less likely to suffer a complete relapse.

Two clinical trials reported two years ago studied 70 and 104 alcoholics, respectively. Dr. Volpicelli and his colleagues reported that after three months, only 23 percent of those who received naltrexone and behavioral therapy had a relapse, compared with 54 percent who received a placebo and counseling.

Dr. Bruce Rounsaville and his colleagues at the Yale University School of Medicine, who used stricter criteria for defining a relapse, found that 39 percent of the naltrexone patients relapsed, compared with 79 percent of those who received only counseling.

Dr. Robert Croop of DuPont is monitoring an ongoing trial at several centers in which more than 500 patients have been treated with the drug, which is trade-named Revia. Although that study is designed to demonstrate safety rather than effectiveness, the success rate, he will report today, is "comparable" to results obtained in the earlier study.

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.